Oncodesign Precision Medicine
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more
Oncodesign Precision Medicine (ALOPM) - Net Assets
Latest net assets as of December 2023: €3.69 Million EUR
Based on the latest financial reports, Oncodesign Precision Medicine (ALOPM) has net assets worth €3.69 Million EUR as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€16.63 Million) and total liabilities (€12.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.69 Million |
| % of Total Assets | 22.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 112.86 |
Oncodesign Precision Medicine - Net Assets Trend (2020–2024)
This chart illustrates how Oncodesign Precision Medicine's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncodesign Precision Medicine (2020–2024)
The table below shows the annual net assets of Oncodesign Precision Medicine from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-429.39K | -111.63% |
| 2023-12-31 | €3.69 Million | -68.67% |
| 2022-12-31 | €11.78 Million | +180.51% |
| 2021-12-31 | €4.20 Million | -39.74% |
| 2020-12-31 | €6.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncodesign Precision Medicine's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1537764933.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €15.10 Million | % |
| Total Equity | €-429.39K | 100.00% |
Oncodesign Precision Medicine Competitors by Market Cap
The table below lists competitors of Oncodesign Precision Medicine ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Earth Gen-Biofuel Inc
PINK:EGBB
|
$4.74K |
|
Austral Group S.A.A.
LIM:AUSTRAC1
|
$4.74K |
|
NB Distressed Debt Inv Extended Life
LSE:NBDX
|
$4.74K |
|
WANT WANT CHINA
BE:4HQ
|
$4.74K |
|
VBX Ltd
AU:VBX
|
$4.73K |
|
China Construction Bank Corp Class H
TW:00939
|
$4.73K |
|
Tattooed Chef Inc.
PINK:TTCFQ
|
$4.73K |
|
Rapid-Line Inc.
OTCGREY:RPDL
|
$4.73K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncodesign Precision Medicine's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,690,700 to -429,389, a change of -4,120,089 (-111.6%).
- Net loss of 7,209,619 reduced equity.
- Other factors increased equity by 3,089,531.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-7.21 Million | -1679.04% |
| Other Changes | €3.09 Million | +719.52% |
| Total Change | €- | -111.63% |
Book Value vs Market Value Analysis
This analysis compares Oncodesign Precision Medicine's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €1.02 | €0.48 | x |
| 2021-12-31 | €0.61 | €0.48 | x |
| 2022-12-31 | €0.71 | €0.48 | x |
| 2023-12-31 | €0.22 | €0.48 | x |
| 2024-12-31 | €-0.02 | €0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncodesign Precision Medicine utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3482.24%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-58.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -2.21% | -3.49% | 0.36x | 1.78x | €-850.76K |
| 2021 | -70.10% | -76.86% | 0.46x | 1.99x | €-3.36 Million |
| 2022 | -1.96% | -2.90% | 0.43x | 1.56x | €-1.41 Million |
| 2023 | -219.22% | -754.61% | 0.06x | 4.51x | €-8.46 Million |
| 2024 | 0.00% | -3482.24% | 0.02x | 0.00x | €-7.17 Million |
Industry Comparison
This section compares Oncodesign Precision Medicine's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncodesign Precision Medicine (ALOPM) | €3.69 Million | -2.21% | 3.51x | $4.73K |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |